Myeloma Novel Drug Discovery Ver 1.2

Inclusion Criteria: 1. Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder 2. Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment 3. Participants aged 18 years of age or above 4. Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling Exclusion Criteria: 1. Participants unable to provide consent 2. Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory